Buprenorphine Drug Profile - Portage College Paramedic Program
Drug Identification and Overview
- Generic Name: buprenorphine
- Trade Names: Belbuca, Brixadi, Buprenex, Butrans, Sublocade
- Classification: Opioid agonist-antagonist
- Supplied Formulations:
- Variety of tablet dosing including buccal films
- Subcutaneous (SUBQ) extended-release solutions for injection
- Sublingual (SL) tablets
- Transdermal patches
- Institutional Origin: Portage College Paramedic Program (Box 417, Lac La Biche, AB T0A2C0)
Actions and Pharmacodynamics
- Mechanism of Action:
- Binds to opiate receptors within the central nervous system (CNS).
- Alters the perception of pain and the physiological response to pain.
- Exhibits partial antagonist properties at both mu (μ) and kappa (κ) receptors.
- Note on Protocol Updates: The description "Partial agonist at the mu receptors and an antagonist at the kappa receptors" was explicitly removed from current guidelines.
Indications and Physician Order Requirements
- Mandatory Order Requirement: All uses of buprenorphine require explicit physician orders.
- Clinical Indications:
- Moderate to severe acute pain.
- Pain control for patients with a documented history of opioid addiction.
- Pain control for severe chronic pain in patients requiring continuous long-term pain management when alternative treatment options (non-opioid medications) are inadequate.
- Suppression of opioid withdrawal symptoms.
Dosage and Administration Guidelines
- Patient Age Restriction: Adult Only
- Analgesia Indications:
- Intravenous / Intramuscular (IV/IM): 0.3mg every 4–6hours as needed.
- Buccal Soluble Film: 75mcg film daily or every 12hours.
- Opioid Use Disorder Indications:
- Sublingual (SL): 8mg once daily.
- Subcutaneous (SUBQ): Administered as prescribed via physician (doses provided per month).
Contraindications
- Known hypersensitivity to buprenorphine or any formulation component.
- Pediatric patients under the age of 18years.
- Pregnancy and breastfeeding.
- Gastrointestinal (GI) obstruction or ileus obstruction.
- Significant respiratory depression.
- QT prolongation.
- Concurrent use of Class I or Class III antiarrhythmics.
Precautions and Risk Factors
- Central Nervous System & Respiratory Interactions:
- Concurrent use with benzodiazepines, alcohol, or other CNS depressants can result in severe respiratory depression.
- Compromised respiratory function, including Chronic Obstructive Pulmonary Disease (COPD), Cor pulmonale, and hypoxia.
- Neurological & Systemic Conditions:
- Increased intracranial pressure (ICP).
- Seizure history.
- Adrenal insufficiency.
- Elderly patients.
- Organ System Impairments (Requiring Dosage Adjustment):
- Renal disease or renal impairment.
- Hepatic disease, alcoholism, or acute pancreatitis: Decrease dose by 21.
- Cardiovascular & Electrolyte Derangements:
- Uncorrected electrical/electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia).
- Unstable heart failure.
- Unstable atrial fibrillation.
- Myocardial ischemia.
- Symptomatic bradycardia.
- Concurrent use of drugs that prolong QT intervals.
- Specific Drug-Drug Interactions:
- Monoamine Oxidase (MAO) Inhibitors: Patients taking MAO inhibitors within the past 14days require a dose reduction of 21.
- Serotonergic Agents: Concurrent use with drugs affecting serotonergic systems increases the risk of Serotonin Syndrome. These agents include:
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- MAO inhibitors
- Tricyclic Antidepressants (TCAs)
- Trazodone
- Mirtazapine
- Serotonin receptor antagonists
- Linezolid
- Methylene blue
- Triptans
Clinical Monitoring and Special Notes
- Adverse Effects & Vital Sign Monitoring:
- Buprenorphine can induce sedation, respiratory depression, and hypotension.
- Mandates continuous monitoring of Level of Consciousness (LOC), vital signs, respiratory rate (RR), and pain score.
- Continuous oxygen saturation (SpO2) monitoring is strictly required.
- Clinical Context & Availability:
- Buprenorphine is a newer medication and continues to be evaluated for specific clinical scenarios, such as hepatic impairment.
- Subcutaneous (SC) doses are reserved for specialized cases managed through hospital settings and represent a relatively new administration pathway in Canada.
Reference Standards and Revisions
- References: Reference 1 (page 318), Reference 4 (pages 249--254), Reference 5 (page 174), Reference 12 (pages 990--991), Alberta Health Services (AHS) Parenteral Manual (October 20, 2023).
- Revision Date: Revised April 2025.